期刊文献+

硼替佐米致多发性骨髓瘤患者急性肺损伤一例 被引量:6

原文传递
导出
摘要 患者男性,69岁.2010年1月入院,诊断为多发性骨髓瘤Ⅲ期A组,IgAλ型.体检:贫血貌;双肺触觉语颤正常对称,听诊闻及呼吸音稍低,未闻及干湿哕音及胸膜摩擦音;余未见异常.予患者PD方案化疗[硼替佐米2.7 mg(1.3mg/m2)第1、4、8、11天,地塞米松40 mg第1、4、8、11天].患者IgA由104.0 g/L降至30.6 g/L,考虑化疗有效.化疗第3天患者出现发热,
出处 《中华内科杂志》 CAS CSCD 北大核心 2011年第6期517-518,共2页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献9

  • 1Miyakoshi S,Kami M,Yuji K,et al.Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.Blood,2006,107:3492-3494.
  • 2Boyer JE,Batra RB,Ascensao JL,et al.Severe pulmonary complication after bortezomib treatment for multiple myeloma.Blood,2006,108:1113.
  • 3Zappasodi P,Dare R,Castagnola C,et al.Rapid response to highdose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.J Clin Oncol,2007,25:3380-3381.
  • 4Pitini V,Arrigo C,Altavilla G,et al.Severe pulmonary complications after bortezomib treatment for multiple mycloma:an unrecognized pulmonary vasculitis? Leuk Res,2007,31:1027-1028.
  • 5Dun X,Yuan Z,Fu W,et al.Severe pulmonary complications after bortezomib treatment in multiple myeloma.Hematol Oncol,2010,28:49-52.
  • 6Rajkumar SV,Richardson PG,Hideshima T,et al.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Onco1,2005,23:630-639.
  • 7Chauhan D,Hideshima T,Anderson KC.Proteasome inhibition in multiple myeloma:therapeutic implication.Annu Rev Pharmacol 0Toxico1,2005,45:465-476.
  • 8Schwartz MD,Moore EE,Moore FA,et al.Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome.Crit Care Med,1996,24:1285-1292.
  • 9Farver CF,Raychaudhuri B,Buhrow LT,et al.Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers.Cytokine,1998,10:868 -871.

同被引文献46

  • 1王亚非,邱录贵,邹德慧,王迎,邓书会,李园,徐燕,钱林生,赵耀中.硼替佐米治疗多发性骨髓瘤后严重肺损伤二例报告并文献复习[J].白血病.淋巴瘤,2008,17(2). 被引量:12
  • 2侯健,周帆,张永贞,景燕.硼替佐米治疗复发、难治性多发性骨髓瘤[J].中国新药与临床杂志,2005,24(7):579-581. 被引量:13
  • 3急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J].中国实用外科杂志,2007,27(1):1-6. 被引量:198
  • 4Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer, 2006, 6:129.
  • 5Boyer JE, Batra RB, Ascensao JL, et al. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood, 2006,108 : 1113.
  • 6Gotoh A, Ohyashiki K, Oshimi K,et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hemalology. IntJ Hematol,2006, 84:406-412.
  • 7Pitini V, A1Tigo C, Ahavilla G, et al. Severe pulmonary complications after bortezomib treatment for multiple myeloma. Leuk Res, 2007,31 : 1027-1028.
  • 8Ohri A, Arena FP. Severe pulmonary complications in African- American patient after bortezomib therapy. Am J Ther ,2006, 13 553-555.
  • 9Zhou X, Sun C, Wang J, et al. Rapid fatal pulmonary complications in a Chinese patient after borlezomib treatment for ALK-negative anaplastie large-cell lymphoma. Clin Lymphoma Myeloma Leuk, 2010, 10:152-154.
  • 10Gupta A, Pandey A, Sethi S. Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol, 2012, 12:184-187.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部